Spectrum Pharmaceuticals Stock Price To Earning
| SPPIDelisted Stock | USD 1.03 0.00 0.00% |
Spectrum Pharmaceuticals fundamentals help investors to digest information that contributes to Spectrum Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Spectrum Stock. The fundamental analysis module provides a way to measure Spectrum Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Spectrum Pharmaceuticals stock.
Spectrum |
Spectrum Pharmaceuticals Company Price To Earning Analysis
Spectrum Pharmaceuticals' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Spectrum Pharmaceuticals Price To Earning | (19.44) X |
Most of Spectrum Pharmaceuticals' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Spectrum Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
CompetitionBased on the latest financial disclosure, Spectrum Pharmaceuticals has a Price To Earning of -19.44 times. This is 175.23% lower than that of the Biotechnology sector and notably lower than that of the Health Care industry. The price to earning for all United States stocks is 167.69% higher than that of the company.
Spectrum Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Spectrum Pharmaceuticals' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Spectrum Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Spectrum Pharmaceuticals by comparing valuation metrics of similar companies.Spectrum Pharmaceuticals is currently under evaluation in price to earning category among related companies.
Spectrum Fundamentals
| Return On Equity | -1.65 | |||
| Return On Asset | -0.38 | |||
| Profit Margin | (2.52) % | |||
| Operating Margin | (2.47) % | |||
| Current Valuation | 185.27 M | |||
| Shares Outstanding | 205.25 M | |||
| Shares Owned By Insiders | 11.00 % | |||
| Shares Owned By Institutions | 22.93 % | |||
| Number Of Shares Shorted | 3.33 M | |||
| Price To Earning | (19.44) X | |||
| Price To Book | 2.40 X | |||
| Revenue | 10.11 M | |||
| Gross Profit | 8.32 M | |||
| EBITDA | (77.06 M) | |||
| Net Income | (75.4 M) | |||
| Cash And Equivalents | 67.96 M | |||
| Cash Per Share | 0.37 X | |||
| Total Debt | 29.43 M | |||
| Debt To Equity | 0.06 % | |||
| Current Ratio | 1.79 X | |||
| Book Value Per Share | 0.13 X | |||
| Cash Flow From Operations | (96.99 M) | |||
| Short Ratio | 3.74 X | |||
| Earnings Per Share | (0.36) X | |||
| Target Price | 1.26 | |||
| Number Of Employees | 86 | |||
| Beta | 2.14 | |||
| Market Capitalization | 211.4 M | |||
| Total Asset | 103.34 M | |||
| Retained Earnings | (1.12 B) | |||
| Working Capital | 58.33 M | |||
| Current Asset | 2.57 M | |||
| Current Liabilities | 2.52 M | |||
| Z Score | -12.54 | |||
| Net Asset | 103.34 M |
About Spectrum Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Spectrum Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Spectrum Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Spectrum Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in Spectrum Stock
If you are still planning to invest in Spectrum Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Spectrum Pharmaceuticals' history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |